Importantly, as dedifferentiated and NCSC states are also responsible for MAPKi-induced cross-resistance to immunotherapy (2, 3), targeting these CD36+ cells by dual PEX3+UGCG inhibition could also potentially sensitize melanoma to combined immunotherapy and MAPKis and prevent cross-resistance. The gene discussed is CD36; the disease is melanoma.